Milan, Italy and New York, New York--(Newsfile Corp. - May 8, 2025) - Genenta Science, SpA (NASDAQ: GNTA), today announced its participation in the D. Boral Capital Inaugural Global Conference ...
MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of ...
Funds available expected to be sufficient for Genenta to continue to operate into the first quarter of 2025Net exchange rate gain of €2.3 millionTax credit of €6.4 million MILAN, Italy and NEW ...
Genenta Science SPA is a clinical-stage biotechnology company pioneering the development of lentivirus-based first-in-class gene and cell therapies in cancer.
09:40 EST Genenta Science (GNTA) SPA (ADR) trading resumesDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now At 40% OFF!Make smarter investments with ...
Every investor in Genenta Science S.p.A. (NASDAQ:GNTA) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are individual investors with ...
Genenta Science SpA chart This market's chart. This is a visual representation of the price action in the market, over a certain period of time. You can use this to help gauge a market’s performance.
Genenta Science, SpA, today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City. To register for one-on ...
Our AI model demonstrates -42% historical accuracy for GNTA predictions, based on advanced machine learning algorithms trained on over 10 years of market data.